



## Interim report

January - September 2022

CombiGene AB (publ)



Continued search  
for promising gene  
therapy assets

Building a  
stronger  
organization

Favorable  
financial  
position





# Interim report January – September 2022 for CombiGene AB (publ)

## July – September 2022

- Net sales: 5,213 (0) TSEK.
- Other operating revenues: 8,313 (423) TSEK.
- Profit from financial items: 3,953 (-10,225) TSEK.
- Earnings per share: 0.20 (-0.52) SEK.

## January – September 2022

- Net sales: 21,354 (0) TSEK.
- Other operating revenues: 21,280 (6,380) TSEK.
- Profit from financial items: 5,785 (-36,483) TSEK.
- Earnings per share: 0.29 (-2.22) SEK.
- Cash and cash equivalents as per the end of the reporting period: 144,940 (66,087) TSEK.
- Equity ratio as per the end of the reporting period: 96 (95)%.

## About CombiGene AB

CombiGene's vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene's business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve preclinical/clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, [info@fnca.se](mailto:info@fnca.se).

## Events during the period

- CombiGene strengthens its management capacity through the recruitment of Peter Ekolind as COO.

## Events after the end of the period

- There have been no significant events after the end of the period.

### For more information: CombiGene AB (publ)

Jan Nilsson, CEO  
Phone: +46(0)704 66 31 63  
[jan.nilsson@combigene.com](mailto:jan.nilsson@combigene.com)

Bert Junno, Chairman  
Phone: +46(0)707 77 22 09  
[bert.junno@combigene.com](mailto:bert.junno@combigene.com)

### Note to the reader

Amounts in brackets refer to the corresponding period of the previous year.



CombiGene's lead project CG01 has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 823282



CombiGene's project CGT2 is supported by the Eurostars Programme. Project ID: 114714

## Building CombiGene of the future

*CombiGene has come a long way since the company was first listed in 2015. At that point in time, the company had one project in early preclinical development – the epilepsy project CG01. Since then, much has happened. CG01 has produced compelling data throughout the preclinical program and was in October 2021 outlicensed to Spark Therapeutics in a deal with a potential value of USD 328.5 million, excluding royalties. The CG01 project is now in late preclinical development. In 2019, CombiGene inlicensed the lipodystrophy project CGT2. Our business development efforts now focus on finding new gene therapy assets to build an even stronger project portfolio.*

### Continued search for promising gene therapy assets

As we have communicated, the assets we are looking for must meet certain criteria in terms of scientific height, patentability, medical need, commercial possibilities, and technology platform. We are also looking for a team that we at CombiGene feel we can collaborate with. People are important! We are primarily seeking AAV-based projects where we have profound knowledge in key areas such as vector design (design of drug candidate), safety aspects, and production. Finding the right gene therapy project to in-license and negotiating the right terms is however no easy task, and it goes without saying that we cannot predict exactly when we will have a new promising project to complement our portfolio.

### Building a stronger organization

In parallel with our focused business development efforts, we are also step by step building a stronger organization which successfully can accommodate new projects. Most recently, we have recruited Peter Ekolind as Chief Operating Officer and Birgitta Ståhl as Senior Director In-licensing. Peter has extensive experience of marketing,

sales and leadership in several global pharmaceutical, biotech and medtech companies in various senior positions, and Birgitta has a long and broad experience from the life science industry, both from a corporate perspective and project leadership in all stages of drug development. With these recruitments, CombiGene has competence and capacity to take on new promising gene therapy projects.

### Favorable financial position

The deal with Spark Therapeutics in October 2021 substantially strengthened CombiGene's financial position. In conjunction with the signing of the agreement, CombiGene received an up-front payment of USD 8.5 million, which significantly strengthened the company's cash position. The deal with Spark also means that Spark assumes all development costs for the continued development of CG01, external as well as CombiGene internal, something which drastically has lowered CombiGene burn rate, creating a favorable financial position where we have the financial strength to inlicense new projects. I would also like to point out that CombiGene's management and Board of Directors work continuously to evaluate the company's financial position and financing options.



### Collaboration with Spark Therapeutics

We have now been working together with Spark since mid-October 2021, and we have developed a very good collaboration. As I have mentioned before, I am particularly pleased with the decision to prioritize the expansion of CG01's clinical development program to include the U.S. as this will allow the project to find a natural foothold in the world's largest pharmaceutical market, and at the same time as Spark can utilize their impressive resources, know-how and networks in an optimal way.

Recently our colleagues at Spark visited us in Stockholm for a very productive two-day meeting, which further reinforced an already productive collaboration.

We are very pleased with the development of the company's projects during 2022 and are now working on the planning for the next financial year.

Jan Nilsson,  
CEO



*On October 12, 2021, Spark Therapeutics licensed the epilepsy project CG01 from CombiGene. The benefits of this agreement are numerous. Firstly, the CG01 project is now jointly run by a company that has resources, knowhow and experience required to advance the CG01 project. Spark is a member of the Roche Group, and the first company to receive FDA approval of a gene therapy for a genetic disease. Secondly, CombiGene's cash position was substantially enhanced by the upfront payment of USD 8.5 million with the potential of another USD 50 million in preclinical and clinical milestone payments. Spark also covers all costs associated with the preclinical development of CG01, external as well as internal CombiGene cost. Thirdly, the agreement rapidly transformed CombiGene into an internationally recognized gene therapy company.*

The scope of the preclinical and clinical phases has, as previously communicated, been expanded. The text below reiterates the terms of the agreement and the expansion of the preclinical and clinical programs.

### **The scope of the agreement**

The collaboration and licensing agreement between CombiGene and Spark is an exclusive worldwide licensing agreement, which gives Spark license to develop the CG01 project throughout the preclinical and clinical phases of the program, to manufacture CG01, and to commercialize CG01 to the global market.

### **The financial terms of the agreement**

The total potential value of the agreement amounts to USD 328.5 million, excluding royalties. The upfront payment, which was made in conjunction with the signing of the agreement, amounted to USD 8.5 million. Milestone payments through the preclinical and clinical phases amount, in total, to USD 50 million. Royalties on future sales of CG01 range from the mid-single digits up to low double-digits based on net sales. All milestone payments will be communicated through CombiGene press releases as they occur.

### **The preclinical development program**

The remainder of the preclinical program is performed by Spark in collaboration with CombiGene. CombiGene continues to run certain aspects of the program while the overall design and execution of program is controlled by Spark. Since the agreement was signed, the preclinical program has been expanded into a cohesive plan to meet the needs of an extended clinical trial submission which includes clinical trials in the

U.S. Studies initiated prior to the agreement with Spark have thereby been integrated in the new and larger program, and in some cases complemented with additional studies. Spark will cover all costs throughout the preclinical development program, including all CombiGene external and internal costs related to CG01.

### **The clinical development program**

Once the preclinical program is completed, Spark will assume responsibility for the design and execution of the clinical development. Since the agreement with Spark, the clinical development program has been extended to include the U.S. All results and knowhow from the preparatory work CombiGene made prior to the agreement has been transferred to Spark. As part of our current agreement, Spark will cover associated costs on any clinical development work.

### **Communication regarding program updates and timeline**

Future updates regarding the CG01 program will be provided by Spark in line with their standard practice.

### **EVENTS IN THE QUARTER**

On September 13-14, representatives from Spark visited the CombiGene team in Stockholm for a very productive two-day meeting, which further reinforced an already productive collaboration.



CombiGene's lead project CG01 has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 823282



## ○ EXCLUSIVE WORLD-WIDE LICENSING AGREEMENT

### Development

The agreement gives Spark license to develop the CG01 project throughout the preclinical and clinical phases of the program.

### Manufacturing

The agreement gives Spark license to manufacture CG01 for preclinical, clinical, and commercial use.

### Commercialization

The agreement gives Spark license to commercialize CG01 to the global market.

## ○ THE FINANCIAL TERMS OF THE AGREEMENT

### Potential value: USD 328.5 million

CombiGene is eligible to receive up to USD 328.5 million, excluding royalties.

### Upfront payment USD 8.5 million

The upfront payment was made in conjunction with the signing of the agreement.

### Milestone payments USD 50 million

CombiGene is eligible to receive up to USD 50 million at preclinical and clinical milestones.

### Royalties

Upon commercialization, CombiGene is eligible for tiered royalties ranging from the mid-single digits up to low double-digits based on net sales.

All milestone payments will be communicated through CombiGene press releases as they occur in line with information rules of Nasdaq First North.

## ○ PRECLINICAL DEVELOPMENT PROGRAM

### Collaboration

The remainder of the preclinical program is performed by Spark in collaboration with CombiGene.

### Extended program

Since the agreement was signed, the preclinical program has been expanded into a cohesive plan to meet the needs of an extended clinical trial submission which includes clinical trials in the U.S.

### CombiGene studies integrated in the new program

Studies initiated prior to the agreement with Spark have been integrated in the extended program.

### Spark covers all costs

Spark will cover all costs throughout the preclinical development program, including all CombiGene external and internal costs related to CG01.

Future updates regarding the CG01 program will be provided by Spark in line with their standard practice and in line with information rules of Nasdaq First North.

## ○ CLINICAL DEVELOPMENT PROGRAM

### Spark will take full responsibility

Once the preclinical program is completed, Spark will assume responsibility for the design and execution of the clinical development.

### Extended program

Since the agreement with Spark, the clinical development program has been extended to include the U.S.

### Knowledge transfer ready

All results and knowhow from the preparatory work CombiGene made prior to the agreement has been transferred to Spark.

### Spark will cover all costs

As part of our current agreement, Spark will cover associated costs on any clinical development work.

*CGT2, CombiGene's project to develop a gene therapy treatment for partial lipodystrophy, is in early preclinical development. The first step in designing gene therapy vectors and testing them in vitro (tests on different liver cells) has been carried out with good results. Since then, several in vivo studies have been performed to evaluate efficacy and gradually narrow down the number of potential gene therapy candidates. The ambition for 2022 is to bring the CGT2 project to the stage where the important proof-of-concept study can be initiated.*

## Grants from the EU's Eurostars international funding program

In February 2021, the Lipodystrophy project was awarded EUR 882,500 in project grants by the EU's Eurostars international funding program. Thanks to this funding CombiGene has established a good collaboration with the University Medical Center Hamburg-Eppendorf, which has a research group with experts in lipid research. Through the Eurostars grant, CombiGene has also been able to strengthen its collaboration with Accelerio, a German CRO company that works on developing analytical methods needed for the future development of CGT2.

## PCT application

In August 2021, CombiGene submitted a so-called PCT application to protect the vectors developed within the CGT2 project. The Patent Cooperation Treaty (PCT) is an international agreement that allows companies to seek patent protection internationally for their innovations in about 150 countries. Within the framework of the PCT, a preliminary assessment of patentability is made before the application can proceed to the national phase where national patent applications are submitted. PCT applications are handled by the World Intellectual Property Organization (WIPO), a self-funding body within the United Nations.

The submitted PCT application builds on the UK patent application filed in 2020 and is a natural next step in ensuring adequate patent protection for the lipodystrophy project CGT2.

## CGT2 Milestones

2019

- In-licensing of the project from Lipigon.

2020

- Design of expression plasmids, which are a starting material for gene-therapeutic vectors CombiGene intends to develop for treatment of partial lipodystrophy.
- In vitro studies (tests on liver cells) show proper protein expression.
- Priority-based patent application filed with the UK Patent Office.
- In vivo studies initiated for evaluation of the different gene therapy vectors.



## EVENTS IN THE QUARTER

On September 29-30, CombiGene met up with representatives from the University Medical Center Hamburg-Eppendorf and Stockholm University within the framework of Eurostars program to review the development of the preclinical program, and map out upcoming activities.

### Important agreement with Professor Ormond MacDougald

In addition to the collaboration agreements with Stockholm University and University Medical Center Hamburg-Eppendorf, CombiGene signed an important agreement with Professor Ormond MacDougald at the University of Michigan Medical School in the U.S. in January 2022. The agreement comprises one pilot study and one main study in which CombiGene's most promising gene therapy candidate within the lipodystrophy project CGT2 will be tried and evaluated.

Professor Ormond MacDougald's new experimental model has large resemblances with partial lipodystrophy in humans, the disorder that CombiGene aims to treat. Professor MacDougald has an entire team working within the lipodystrophy field and the team has acquired extensive knowledge that will benefit CombiGene's CGT2 project.



2021

- The lipodystrophy project receives EUR 882,500 in development grants from the EU Eurostars program.
- PCT application submitted.

2022

- CombiGene signs agreement with University of Michigan to evaluate the leading gene therapy candidate within the lipodystrophy project CGT2.



CombiGene's project CGT2 is supported by the Eurostars Programme. Project ID: 114714

## Value-creating business development through development of gene therapy assets and international partnering

*CombiGene has for several years worked long-term to establish the company as an interesting player in the international pharmaceutical market and has gradually built up an extensive network of partners with specific competences within gene therapy. Since CombiGene signed the collaboration and licensing agreement for CG01 with Spark Therapeutics in 2021, the company has intensified its efforts to find new projects to in-license.*

CombiGene's business development spans three areas:

- In-licensing of new projects with high potential for value creation within CombiGene.
- Alliances with partners and service companies that allow CombiGene to further develop licensed projects.
- Out-licensing of projects that target significant patient populations in late preclinical/early clinical phase. When it comes to drug candidates targeting limited patient populations, CombiGene may drive development and commercialization under its own management or seek strategic partnerships.

So far, CombiGene's business development has resulted in the in-licensing of the CGT2 lipodystrophy project from Lipigon. Furthermore, CombiGene has established collaboration with a number of CRO and CDMO companies within the CG01 and CGT2 projects, and out-licensed the CG01 epilepsy project to Spark Therapeutics in an agreement with a potential value of USD 328.5 million excluding royalties.

### Focus on in-licensing new projects

With the agreement with Spark, CombiGene is well placed to take the next step in the company's development and the in-licensing of additional gene therapy projects will be in focus.

CombiGene is primarily seeking AAV-based projects because it is within this technology platform that the company has established knowledge in key areas such as vector design (design of drug candidate), safety aspects, and production. Similarly, the areas of disease that are in focus are those where CombiGene has a solid knowledge, i.e., diseases of the central nervous system and metabolic diseases.

Having said that, CombiGene will at the same time have an open attitude towards all potential projects and evaluate each opportunity on its own merits. CombiGene regularly participates in important partnering conferences and the company has continuous dialogues within academia as well as industry to identify interesting projects.



## The share

*The share capital of the Company shall amount to no less than SEK 990,000 and no more than SEK 3,960,000 divided into no less than 19,800,000 shares and no more than 79,200 000 shares. CombiGene has one class of share. Each share carries equal rights to CombiGene's assets and profits and is entitled to one vote at the Annual General Meeting. The quota value is SEK 0.05. The CombiGene share register is maintained electronically by Euroclear.*

*The share trades under the name CombiGene, the ticker is COMBI, and the ISIN-Code is SE0016101935.*

### Authorization to issue new shares, warrants or convertibles

The AGM 2022 resolved, in accordance with the board of directors' proposal, to authorize the board of directors to, at one or several occasions and for the period up until the next annual general meeting, resolve to increase the company's share capital by issuing new shares, warrants or convertibles. Such issue resolution may be carried out with or without deviation from the shareholders' preferential rights and with or without provisions for contribution in kind, set-off or other conditions. The total number of shares that may be issued, or, as regards issue of convertibles or warrants, issued by conversion or exercise, under the authorization shall not be limited in any

other way than by the limits for the share capital and number of shares, as set forth from time to time in the registered articles of association.

### LTI 2022

The AGM 2022 resolved, in accordance with the board of directors' proposal, on the implementation of a performance-based incentive program, named LTI 2022, directed issue of 900,000 warrants, transfer of the warrants to participants in LTI 2022 and transfer of warrants to cover costs for LTI 2022 and authorization to enter into swap agreement. A more detailed description of LTI 2022 can be found in the notice convening the Annual General Meeting 2022.

### Largest shareholders

Ten largest shareholders as of September 30, 2022	Total holdings	Holding %
Avanza Pension	1,282,754	6.48%
Nordqvist, Jan Ivar	1,258,529	6.36%
Myrlid AS	980,138	4.95%
Thoren Tillväxt AB	494,894	2.50%
Nordnet Pensionsförsäkring AB	448,626	2.27%
Försäkringsaktiebolaget Skandia	279,867	1.41%
Olsson, Per Magnus	240,764	1.22%
Ferstad, Arne	214,072	1.08%
Stenfors, Olle	200,000	1.01%
Nordnet Livsförsäkring AS	185,804	0.94%





### Income and earnings

Net sales consist of milestone payments and compensation from license and cooperation agreements. Due to the nature of the business, there may be large fluctuations between revenues for different periods when revenue from milestone payments is recognized at the time when the performance obligations are met. The Group has a total net sale of SEK 21,354 (0) thousand during the period January-September. Other operating revenues amounts to SEK 21,280 (6,380) thousand, and consist of SEK 0 (4,586) thousand which refers to the revenue-earned portion of the grant received from Horizon 2020 and SEK 1,440 (1,404) thousand which refers to the revenue-earned portion of the grant received from Eurostars, and primarily realized and unrealized foreign exchange gains. Operating profit for the period amounted to SEK 5,785 (-36,483) thousand. The main costs during the period have been related to research & development, fees for consultants and personnel costs.

### Cash flow and financial position

Cash flow for the period January-September amounts to SEK -10,412 TSEK. Cash and cash equivalents at the end of the period amounts to 144,940 TSEK. The equity ratio is 96,3%.

### Liquidity and financing

The EU's Eurostars program, which is aimed at small and medium-sized enterprises wishing to collaborate on research and development projects, has allocated development grants to the CGT2 project. The total grant for CombiGene amounts to SEK 5 million, of which SEK 2.5 million has so far been paid out.

The board and company management continuously evaluate alternatives to ensure the company's financing in the short and medium term.

### The share

The average number of shares for the period is 19,801,197. All shares are of the same type and have the same voting rights. At the Annual General Meeting of CombiGene on 25 May 2021 a reverse share split was resolved upon, whereby twenty (20) existing shares were consolidated into one (1) new share. Through the reverse share split, the number of shares in CombiGene decreased from 396,023,950 to 19,801,197. For comparability, a retroactive adjustment has been made to the number of shares.

### Incentive programs and warrants

The 2022 Annual General Meeting resolved on a performance-based incentive program (LTI 2022) for certain employees and consultants in CombiGene. The duration of the program is approximately three years and will be offered to nine current employees and consultants, or newly hired persons, in the

company. A maximum of 617,220 Performance Share Rights may be allocated to the participants, corresponding to approximately 3 percent of the outstanding shares and votes in the Company, as well as 282,780 warrants issued to hedge the Company's cost under the Program, which corresponds to approximately 1.4 percent of the outstanding shares and votes in the Company. In accordance with the Board's proposal, the AGM resolved on a directed issue of 900,000 warrants with the right to subscribe for new shares in the company for the implementation of LTI 2022.

### Employees

The number of employees in the Group at the end of the period was 11 (7), of whom 6 (4) are women.

### Risks and uncertainties

A drug development company of CombiGene's type is characterized by a high operational and financial risk. The Company is dependent on current and future licensing, collaboration, and other agreements with experienced partners for the development and successful commercialization of existing and future drug candidates. The most significant example of this is CombiGene's exclusive global collaboration and licensing agreement with Spark Therapeutics, which has a potential total value of USD 328.5 million excluding royalties. The agreement with Spark is thus of great importance for CombiGene's future operations, earnings, and financial position. Other factors that may negatively affect the likelihood of commercial success include, among other things, the risk that CombiGene's gene therapies are not deemed safe or not effective, and the risk that the business may not receive the necessary funding.

### Principles for preparation of the interim report

CombiGene prepares its financial reports in accordance with the Swedish Annual Accounts Act and BFNAR 2012:1 (K3) Annual Accounts and Consolidated Accounts. The same accounting principles have been applied in this interim report as were applied in the most recent annual report.

### Review by auditors

This report has not been subject to review by the company's auditors.

### Future reporting date

Year-end report January - December 2022, 17 February 2023.

### For further information, please contact:

CombiGene AB (publ), Jan Nilsson, CEO  
Phone: +46(0)704 66 31 63  
Email: [jan.nilsson@combigene.com](mailto:jan.nilsson@combigene.com)

### Stockholm, 11 November 2022, CombiGene AB (publ)

Bert Junno  
Chairman

Peter Nilsson  
Board member

Jonas Ekblom  
Board member

Per Lundin  
Board member

Gunilla Lundmark  
Board member

## Group income statement in summary

Figures in TSEK	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec
Net sales	5,213	0	21,354	0	84,042
Other operating revenues	8,313	423	21,280	6,380	7,478
<b>Operating expenses</b>					
Other external expenses	-5,912	-7,733	-25,698	-33,053	-54,591
Personnel expenses	-2,985	-2,123	-8,811	-6,914	-11,692
Other operating expenses	-28	-143	-392	-950	-1,677
<b>Profit/loss before depreciation</b>	<b>4,602</b>	<b>-9,576</b>	<b>7,731</b>	<b>-34,537</b>	<b>23,560</b>
Depreciation	-649	-649	-1,946	-1,946	-2,595
<b>Profit/loss after depreciation</b>	<b>3,953</b>	<b>-10,225</b>	<b>5,785</b>	<b>-36,483</b>	<b>20,965</b>
Net financial income/expense	0	0	0	0	0
<b>Income after net financial items</b>	<b>3,953</b>	<b>-10,225</b>	<b>5,785</b>	<b>-36,483</b>	<b>20,965</b>
Tax	0	0	0	0	0
<b>Net profit/loss for the period</b>	<b>3,953</b>	<b>-10,225</b>	<b>5,785</b>	<b>-36,483</b>	<b>20,965</b>
Attributable to					
Parent company shareholders	3,953	-10,225	5,785	-36,483	20,965
Earnings per share before dilution	0.20	-0.52	0.29	-2.22	1.21
Earnings per share after dilution	0.20	-0.52	0.29	-2.22	1.21
Average number of shares before dilution	19,801,197	19,801,197	19,801,197	16,460,128	17,311,414
Average number of shares after dilution	19,801,197	19,801,197	19,801,197	16,460,128	17,311,414
<i>Total outstanding shares</i>	<i>19,801,197</i>	<i>19,801,197</i>	<i>19,801,197</i>	<i>19,801,197</i>	<i>19,801,197</i>



## Group balance sheet in summary

Figures in TSEK	2022 30 Sep	2021 30 Sep	2021 31 Dec
<b>ASSETS</b>			
Intangible assets	19,652	22,247	21,599
<b>Total fixed assets</b>	<b>19,652</b>	<b>22,247</b>	<b>21,599</b>
<b>Current assets</b>			
Inventories	0	824	0
Other receivables	5 608	16 534	7 879
Cash and bank balances	144 940	66 087	136 744
<b>Total current assets</b>	<b>150 548</b>	<b>83 445</b>	<b>144 622</b>
<b>Total assets</b>	<b>170 200</b>	<b>105 692</b>	<b>166 221</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES</b>			
Share capital	990	990	990
Other capital contribution	224,124	224,124	224,124
Other shareholders' equity	-66,835	-87,800	-87,800
Profit/loss for the year	5,785	-36,483	20,965
<b>Equity attributable to parent company shareholders</b>	<b>164,064</b>	<b>100,831</b>	<b>158,279</b>
<b>Liabilities</b>			
Current liabilities	6,136	4,861	7,942
<b>Total liabilities</b>	<b>6,136</b>	<b>4,861</b>	<b>7,942</b>
<b>Total shareholders' equity and liabilities</b>	<b>170,200</b>	<b>105,692</b>	<b>166,221</b>

## Summary report of changes in the Group's shareholders' equity

Figures in TSEK	Share capital	Other capital contribution	Accumulated profit/loss	Total share-holders' equity
Balance brought forward	990	224,124	-66,835	158,279
Net profit/loss for the period			5,785	5,785
Amount as per the end of the reporting period	990	224,124	-61,050	164,064

## Group cash flow statement in summary

Figures in TSEK	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec
Cash flow from operating activities	-10,412	-48,542	22,115
Cash flow from investing activities	0	-148	-148
Cash flow from financing activities	0	65,881	65,881
<b>Cash flow for the period</b>	<b>-10,412</b>	<b>17,192</b>	<b>87,849</b>
Liquid assets at the beginning of the reporting period	136,744	48,895	48,895
Exchange rate difference cash and cash equivalents	18,609	0	0
<b>Liquid assets at the end of the reporting period</b>	<b>144,940</b>	<b>66,087</b>	<b>136,744</b>

## Parent Company income statement in summary

Figures in TSEK	2022 Jul-Sep	2021 Jul-Sep	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec
Net sales	5,213	0	21,354	0	84,042
Other operating revenues	8,341	423	21,280	6,380	7,478
<b>Operating expenses</b>					
Other external expenses	-5,905	-7,700	-25,640	-32,989	-54,517
Personnel expenses	-2,985	-2,123	-8,811	-6,914	-11,692
Other operating expenses	-26	-143	-390	-950	-1,677
<b>Profit/loss before depreciation</b>	<b>4,638</b>	<b>-9,543</b>	<b>7,792</b>	<b>-34,473</b>	<b>23,634</b>
Depreciation	-75	-75	-225	-225	-300
<b>Profit/loss after depreciation</b>	<b>4,563</b>	<b>-9,618</b>	<b>7,567</b>	<b>-34,698</b>	<b>23,334</b>
Net financial income/expense	-574	-574	-1,721	-1,721	-2,295
<b>Income after net financial items</b>	<b>3,989</b>	<b>-10,192</b>	<b>5,845</b>	<b>-36,419</b>	<b>21,039</b>
Tax	0	0	0	0	0
<b>Net profit/loss for the period</b>	<b>3,989</b>	<b>-10,192</b>	<b>5,845</b>	<b>-36,419</b>	<b>21,039</b>



## Parent Company balance sheet in summary

Figures in TSEK	2022 30 Sep	2021 30 Sep	2021 31 Dec
<b>ASSETS</b>			
Intangible assets	4,162	4,462	4,387
Financial assets	19,159	21,454	20,880
<b>Total fixed assets</b>	<b>23,321</b>	<b>25,916</b>	<b>25,267</b>
<b>Current assets</b>			
Inventories	0	824	0
Other receivables	6 354	17 183	8 563
Cash and bank balances	144 747	65 897	136 545
<b>Total current assets</b>	<b>151 101</b>	<b>83 904</b>	<b>145 108</b>
<b>Total assets</b>	<b>174 422</b>	<b>109 820</b>	<b>170 376</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES</b>			
<i>Restricted equity</i>			
Share capital	990	990	990
Statutory reserve	4	4	4
Reserve for development expenses	760	760	760
<i>Non-restricted equity</i>			
Share premium reserve	165,826	165,826	165,826
Accumulated loss including profit/loss for the year	745	-62,559	-5,101
<b>Total shareholders' equity</b>	<b>168,323</b>	<b>105,020</b>	<b>162,478</b>
<b>Liabilities</b>			
Current liabilities	6,099	4,800	7,898
<b>Total liabilities</b>	<b>6,099</b>	<b>4,800</b>	<b>7,898</b>
<b>Total shareholders' equity and liabilities</b>	<b>174,422</b>	<b>109,820</b>	<b>170,376</b>

## Summary report of changes in the Parent Company's shareholders' equity

Figures in TSEK	Share capital	Statutory reserve	Reserve for development expenses	Share premium reserve	Accumulated profit/loss	Total shareholders' equity
<b>Balance brought forward</b>	<b>990</b>	<b>4</b>	<b>760</b>	<b>165,826</b>	<b>-5,101</b>	<b>162,478</b>
Net profit/loss for the period					5,845	5,845
<b>Amount as per the end of the reporting period</b>	<b>990</b>	<b>4</b>	<b>760</b>	<b>165,826</b>	<b>745</b>	<b>168,323</b>

## Parent Company cash flow statement in summary

Figures in TSEK	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec
Cash flow from operating activities	-10,407	-48,539	22,109
Cash flow from investing activities	0	-148	-148
Cash flow from financing activities	0	65,881	65,881
<b>Cash flow for the period</b>	<b>-10,407</b>	<b>17,195</b>	<b>87,843</b>
Liquid assets at the beginning of the reporting period	136,545	48,703	48,703
Exchange rate difference cash and cash equivalents	18,609	0	0
<b>Liquid assets at the end of the reporting period</b>	<b>144,747</b>	<b>65,897</b>	<b>136,545</b>

## Group financial key ratios

Figures in TSEK	2022 Jan-Sep	2021 Jan-Sep	2021 Jan-Dec
Earnings per share before dilution, SEK	0.29	-2.22	1.21
Earnings per share after dilution, SEK	0.29	-2.22	1.21
Shareholders' equity per share, SEK	8.29	5.09	7.99
Equity ratio, %	96.39	95.40	95.22
Average number of shares before dilution	19,801,197	16,460,128	17,311,414
Average number of shares after dilution	19,801,197	16,460,128	17,311,414
Total outstanding shares	19,801,197	19,801,197	19,801,197

## Share capital development

Year	Event	Total share capital (SEK)	Change (SEK)	Total shares	Change shares	Quotient (SEK)
1990	Company registration	50,000	50,000	500	500	100.00
1997	Bonus issue	100,000	50,000	1,000	500	100.00
2010	New share issue	102,600	2,600	1,026	26	100.00
2013	New share issue	143,600	41,000	1,436	410	100.00
2014	Bonus issue	574,400	430,800	5,744	4,308	100.00
2014	New share issue	604,400	30,000	6,044	300	100.00
2014	Split 1 000:1	604,400	0	6,044,000	6,037,956	0.10
2014	New share issue	884,400	280,000	8,844,000	2,800,000	0.10
2015	New share issue	1,134,400	250,000	11,344,000	2,500,000	0.10
2015	New share issue	1,138,197	3,797	11,381,970	37,970	0.10
2016	New share issue	1,180,159	41,962	11,801,590	419,620	0.10
2017	New share issue	1,652,223	472,064	16,522,230	4,720,637	0.10
2018	New share issue	1,719,783	67,560	17,197,836	675,596	0.10
2018	New share issue	5,159,348	3,439,565	51,593,476	34,395,650	0.10
2019	New share issue	6,372,384	1,213,036	63,723,836	12,130,360	0.10
2019	New share issue	6,373,090	706	63,730,896	7,060	0.10
2019	New share issue	6,505,365	132,275	65,053,647	1,322,751	0.10
2020	New share issue	11,762,201	5,256,836	117,622,007	52,568,360	0.10
2020	New share issue	12,562,201	800,000	125,622,007	8,000,000	0.10
2020	New share issue	14,721,013	2,158,813	147,210,132	21,588,125	0.10
2020	New share issue	17,666,081	2,945,068	176,660,811	29,450,679	0.10
2020	New share issue	17,822,218	156,137	178,222,176	1,561,365	0.10
2020	New share issue	20,768,890	2,946,672	207,688,899	29,466,723	0.10
2020	New share issue	22,927,702	2,158,813	229,277,024	21,588,125	0.10
2021	New share issue	39,602,395	16,674,693	396,023,950	166,746,926	0.10
2021	Reverse share split (1:20)	39,602,395	0	19,801,197	-376,222,753	2.00
2021	Reduction of share capital	990,060	-38,612,335	19,801,197	0	0.05
At the end of the period		990,060		19,801,197		0.05



**AED**

Anti-Epileptic Drug.

**Clinical phase I**

Phase I refers to the first instance of testing of a candidate drug on humans. Phase I trials are often conducted with a small group of healthy volunteer trial subjects to determine the safety and dosage of an as yet non-approved treatment method.

**Clinical phase II**

Phase II trials refer to a pharmaceutical product under development that is administered to a small group of patients to study the safety, dosage and efficacy.

**Clinical phase III**

Phase III studies include a sufficient number of patients to meet regulatory prerequisites for approval. The aim is to determine the statistical significance with respect to the effect of a new candidate drug, without major side effects and under carefully controlled real-world conditions. The new drug is sometimes compared with an established treatment, such as an approved drug.

**Clinical studies**

Research studies that explore whether a new, as yet non-approved, drug, medical strategy, treatment, or device is safe and effective for humans.

**GMP**

A Good Manufacturing Practice (GMP) is a system for ensuring that pharmaceutical products are consistently produced and controlled according to quality standards. Permits for GMP are granted by the Food and Drug Administration in the country in question and the process is characterized by extremely rigid and high demands on quality in all respects.

**In vitro**

A term used in biomedical science to describe a biological process made to occur in a laboratory vessel or other controlled experimental environment rather than within a living organism.

**In vivo**

A term used in biomedical science to describe an experimental biological process, and observations thereof, made to occur within a living organism.

**Neuropeptide**

Neuropeptides are small, protein-like molecules (peptides) that are used by neurons to communicate with each other.

**NPY**

Neuropeptide Y, a neurotransmitter that is widely distributed in the central nervous systems of animals and humans.

**Proof of concept**

Documented evidence that a potential product or method has the intended effect.

**Viral vector**

Viral vectors are tools that are used to deliver genetic material to cells. Examples of viral vectors are lentivirus, adeno-associated virus (AAV), retrovirus and adenovirus. AAV vectors are non-hazardous viruses that can infect human cells without causing disease and can be used to deliver genetic material into human cells.



CombiGene's lead project CG01 has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 823282



CombiGene's project CGT2 is supported by the Eurostars Programme. Project ID: 114714



# CombiGene

## – The gene therapy explorer

CombiGene's vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene's business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, [info@fnca.se](mailto:info@fnca.se).



[www.combigene.com](http://www.combigene.com)

CombiGene AB (publ)  
Agavägen 52A, SE-181 55 Lidingö, Sweden  
[info@combigene.com](mailto:info@combigene.com)